RU2005110409A - Производные 4-аминопиперидина, способы их получения и использование в качестве медикаментов - Google Patents
Производные 4-аминопиперидина, способы их получения и использование в качестве медикаментов Download PDFInfo
- Publication number
- RU2005110409A RU2005110409A RU2005110409/04A RU2005110409A RU2005110409A RU 2005110409 A RU2005110409 A RU 2005110409A RU 2005110409/04 A RU2005110409/04 A RU 2005110409/04A RU 2005110409 A RU2005110409 A RU 2005110409A RU 2005110409 A RU2005110409 A RU 2005110409A
- Authority
- RU
- Russia
- Prior art keywords
- piperidinecarboxylate
- tert
- butyl
- anilino
- fluoro
- Prior art date
Links
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical class NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 title claims abstract 7
- 238000000034 method Methods 0.000 title claims abstract 5
- 239000003814 drug Substances 0.000 title claims 4
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- ORKNCAZKJYJQJX-UHFFFAOYSA-N n-(3-fluorophenyl)-n-[(4-fluorophenyl)methyl]piperidin-4-amine Chemical compound C1=CC(F)=CC=C1CN(C=1C=C(F)C=CC=1)C1CCNCC1 ORKNCAZKJYJQJX-UHFFFAOYSA-N 0.000 claims 2
- NHENINYMLDQOSV-UHFFFAOYSA-N n-(3-fluorophenyl)-n-[(4-methylphenyl)methyl]piperidin-4-amine Chemical compound C1=CC(C)=CC=C1CN(C=1C=C(F)C=CC=1)C1CCNCC1 NHENINYMLDQOSV-UHFFFAOYSA-N 0.000 claims 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- WFFKVJOHXLLCQR-UHFFFAOYSA-N n-(4-fluorophenyl)-n-[(4-fluorophenyl)methyl]piperidin-4-amine Chemical compound C1=CC(F)=CC=C1CN(C=1C=CC(F)=CC=1)C1CCNCC1 WFFKVJOHXLLCQR-UHFFFAOYSA-N 0.000 claims 1
- XZCRHOZHVXRABP-UHFFFAOYSA-N n-(4-fluorophenyl)-n-[(4-methylphenyl)methyl]piperidin-4-amine Chemical compound C1=CC(C)=CC=C1CN(C=1C=CC(F)=CC=1)C1CCNCC1 XZCRHOZHVXRABP-UHFFFAOYSA-N 0.000 claims 1
- VLXRFBGQEPJBBY-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-n-phenylpiperidin-4-amine Chemical compound C1=CC(C)=CC=C1CN(C=1C=CC=CC=1)C1CCNCC1 VLXRFBGQEPJBBY-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- -1 tert-butyl 4- {4-fluoro [4- (trifluoromethyl)] anilino} -1-piperidinecarboxylate Chemical compound 0.000 claims 1
- ZJWJLMVMSWQJEG-UHFFFAOYSA-N tert-butyl 4-(3-fluoroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC(F)=C1 ZJWJLMVMSWQJEG-UHFFFAOYSA-N 0.000 claims 1
- DPSZFTDDJZNGLN-UHFFFAOYSA-N tert-butyl 4-(3-methylanilino)piperidine-1-carboxylate Chemical compound CC1=CC=CC(NC2CCN(CC2)C(=O)OC(C)(C)C)=C1 DPSZFTDDJZNGLN-UHFFFAOYSA-N 0.000 claims 1
- VIQBBHKRRVSVDA-UHFFFAOYSA-N tert-butyl 4-(4-methylanilino)piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 VIQBBHKRRVSVDA-UHFFFAOYSA-N 0.000 claims 1
- ZWMVDPGCRIWTFX-UHFFFAOYSA-N tert-butyl 4-(n-benzyl-4-fluoroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=CC=C1 ZWMVDPGCRIWTFX-UHFFFAOYSA-N 0.000 claims 1
- DHMSZXLJNHHNOQ-UHFFFAOYSA-N tert-butyl 4-[3-fluoro-n-[(4-fluorophenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=C(F)C=C1 DHMSZXLJNHHNOQ-UHFFFAOYSA-N 0.000 claims 1
- PUVOHENDVKWSII-UHFFFAOYSA-N tert-butyl 4-[3-fluoro-n-[(4-methylphenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1CN(C=1C=C(F)C=CC=1)C1CCN(C(=O)OC(C)(C)C)CC1 PUVOHENDVKWSII-UHFFFAOYSA-N 0.000 claims 1
- WHFOYQBREFHZHD-UHFFFAOYSA-N tert-butyl 4-[3-fluoro-n-[[4-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=C(C(F)(F)F)C=C1 WHFOYQBREFHZHD-UHFFFAOYSA-N 0.000 claims 1
- PBVWEAJGULJUQL-UHFFFAOYSA-N tert-butyl 4-[3-methyl-n-[[4-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=CC(=CC=2)C(F)(F)F)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 PBVWEAJGULJUQL-UHFFFAOYSA-N 0.000 claims 1
- FSMNNLRYDBDHPZ-UHFFFAOYSA-N tert-butyl 4-[4-chloro-n-[(4-fluorophenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(Cl)=CC=1)CC1=CC=C(F)C=C1 FSMNNLRYDBDHPZ-UHFFFAOYSA-N 0.000 claims 1
- NRQZKAXUEQDBQD-UHFFFAOYSA-N tert-butyl 4-[4-fluoro-n-[(4-methylphenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1CN(C=1C=CC(F)=CC=1)C1CCN(C(=O)OC(C)(C)C)CC1 NRQZKAXUEQDBQD-UHFFFAOYSA-N 0.000 claims 1
- OQJCQJFNVTWAGU-UHFFFAOYSA-N tert-butyl 4-[4-fluoro-n-[[3-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=CC(C(F)(F)F)=C1 OQJCQJFNVTWAGU-UHFFFAOYSA-N 0.000 claims 1
- VIDZZKSGWLBOFX-UHFFFAOYSA-N tert-butyl 4-[4-methyl-n-[[4-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(C(F)(F)F)C=C1 VIDZZKSGWLBOFX-UHFFFAOYSA-N 0.000 claims 1
- MHCRFLOBVBFWPR-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-dichlorophenyl)methyl]-3-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=C(Cl)C(Cl)=C1 MHCRFLOBVBFWPR-UHFFFAOYSA-N 0.000 claims 1
- KMQWWPNSTVQKSN-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-dichlorophenyl)methyl]-3-methylanilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=C(Cl)C(Cl)=CC=2)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 KMQWWPNSTVQKSN-UHFFFAOYSA-N 0.000 claims 1
- ZCQPQTVFPGAMNL-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-dichlorophenyl)methyl]-4-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=C(Cl)C(Cl)=C1 ZCQPQTVFPGAMNL-UHFFFAOYSA-N 0.000 claims 1
- RYULODSEUFYVIP-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-dichlorophenyl)methyl]-4-methylanilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(Cl)C(Cl)=C1 RYULODSEUFYVIP-UHFFFAOYSA-N 0.000 claims 1
- WTDNXQQXQAGMNQ-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-dichlorophenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)CC1=CC=C(Cl)C(Cl)=C1 WTDNXQQXQAGMNQ-UHFFFAOYSA-N 0.000 claims 1
- FUCBWEUARADGFU-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-difluorophenyl)methyl]-3-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=C(F)C(F)=C1 FUCBWEUARADGFU-UHFFFAOYSA-N 0.000 claims 1
- YSXGOPWBLJYOQM-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-difluorophenyl)methyl]-3-methylanilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=C(F)C(F)=CC=2)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 YSXGOPWBLJYOQM-UHFFFAOYSA-N 0.000 claims 1
- QKTPQQYFZANRNR-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-difluorophenyl)methyl]-4-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=C(F)C(F)=C1 QKTPQQYFZANRNR-UHFFFAOYSA-N 0.000 claims 1
- KAGNURBEUTXFHJ-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-difluorophenyl)methyl]-4-methylanilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(F)C(F)=C1 KAGNURBEUTXFHJ-UHFFFAOYSA-N 0.000 claims 1
- KQAHMEADIQYWPU-UHFFFAOYSA-N tert-butyl 4-[n-[(3,4-difluorophenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)CC1=CC=C(F)C(F)=C1 KQAHMEADIQYWPU-UHFFFAOYSA-N 0.000 claims 1
- NCXATLCENJGZEZ-UHFFFAOYSA-N tert-butyl 4-[n-[(3-chlorophenyl)methyl]-3-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=CC(Cl)=C1 NCXATLCENJGZEZ-UHFFFAOYSA-N 0.000 claims 1
- AQIHGXOWQRJHOK-UHFFFAOYSA-N tert-butyl 4-[n-[(3-chlorophenyl)methyl]-3-methylanilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=C(Cl)C=CC=2)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 AQIHGXOWQRJHOK-UHFFFAOYSA-N 0.000 claims 1
- QRXFMMTUBJRVTL-UHFFFAOYSA-N tert-butyl 4-[n-[(3-chlorophenyl)methyl]-4-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=CC(Cl)=C1 QRXFMMTUBJRVTL-UHFFFAOYSA-N 0.000 claims 1
- WLAOCQSHSHZXBF-UHFFFAOYSA-N tert-butyl 4-[n-[(3-chlorophenyl)methyl]-4-methylanilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=CC(Cl)=C1 WLAOCQSHSHZXBF-UHFFFAOYSA-N 0.000 claims 1
- FPDDPGYRYXTCBH-UHFFFAOYSA-N tert-butyl 4-[n-[(3-chlorophenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC(Cl)=C1 FPDDPGYRYXTCBH-UHFFFAOYSA-N 0.000 claims 1
- VLASAWHSTDVGRJ-UHFFFAOYSA-N tert-butyl 4-[n-[(4-chlorophenyl)methyl]-3-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=C(F)C=CC=1)CC1=CC=C(Cl)C=C1 VLASAWHSTDVGRJ-UHFFFAOYSA-N 0.000 claims 1
- RYQRFXJOCVNKAN-UHFFFAOYSA-N tert-butyl 4-[n-[(4-chlorophenyl)methyl]-3-methylanilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=CC(Cl)=CC=2)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 RYQRFXJOCVNKAN-UHFFFAOYSA-N 0.000 claims 1
- GEDIBBKZPJRVLO-UHFFFAOYSA-N tert-butyl 4-[n-[(4-chlorophenyl)methyl]-4-fluoroanilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(F)=CC=1)CC1=CC=C(Cl)C=C1 GEDIBBKZPJRVLO-UHFFFAOYSA-N 0.000 claims 1
- TXYSUYOLHMKRHC-UHFFFAOYSA-N tert-butyl 4-[n-[(4-chlorophenyl)methyl]-4-methylanilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(Cl)C=C1 TXYSUYOLHMKRHC-UHFFFAOYSA-N 0.000 claims 1
- UZLVUNIKDAWAIG-UHFFFAOYSA-N tert-butyl 4-[n-[(4-fluorophenyl)methyl]-3-methylanilino]piperidine-1-carboxylate Chemical compound CC1=CC=CC(N(CC=2C=CC(F)=CC=2)C2CCN(CC2)C(=O)OC(C)(C)C)=C1 UZLVUNIKDAWAIG-UHFFFAOYSA-N 0.000 claims 1
- BYCANGPTOOZUIP-UHFFFAOYSA-N tert-butyl 4-[n-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(=CC=1)C(F)(F)F)CC1=CC=C(F)C=C1 BYCANGPTOOZUIP-UHFFFAOYSA-N 0.000 claims 1
- XDFBTRFRCCMDNQ-UHFFFAOYSA-N tert-butyl 4-[n-[(4-fluorophenyl)methyl]-4-methylanilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N(C1CCN(CC1)C(=O)OC(C)(C)C)CC1=CC=C(F)C=C1 XDFBTRFRCCMDNQ-UHFFFAOYSA-N 0.000 claims 1
- YFSDZQHLKMURJK-UHFFFAOYSA-N tert-butyl 4-[n-[(4-methylphenyl)methyl]anilino]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1CN(C=1C=CC=CC=1)C1CCN(C(=O)OC(C)(C)C)CC1 YFSDZQHLKMURJK-UHFFFAOYSA-N 0.000 claims 1
- FTSWUMAPHSKQAN-UHFFFAOYSA-N tert-butyl 4-[n-[[3-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC(C(F)(F)F)=C1 FTSWUMAPHSKQAN-UHFFFAOYSA-N 0.000 claims 1
- CSUGWJKEEIQWIU-UHFFFAOYSA-N tert-butyl 4-[n-[[4-(trifluoromethyl)phenyl]methyl]anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 CSUGWJKEEIQWIU-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (14)
2. Производное 4-аминопиперидина по п.1, в котором R2 представляет собой водород, фтор или метил; и R4 представляет собой водород, фтор, хлор или трифторметил.
3. Производное 4-аминопиперидина по п.1, в котором R1 представляет собой водород, фтор или хлор; R2 представляет собой водород, фтор или метил; R3 представляет собой водород, фтор, хлор или метил; и R4 представляет собой водород, фтор или хлор.
4. Производное 4-аминопиперидина по п.1, в котором R1 представляет собой водород или фтор; R2 представляет собой водород или фтор; R3 представляет собой фтор или метил; и R4 представляет собой водород.
5. Производное 4-аминопиперидина по п.1, выбранное из группы, состоящей N-(4-метилбензил)-N-фенил-4-пиперидинамина; N-(4-фторбензил)-N-(3-фторфенил)-4-пиперидинамина; N-(3-фторфенил)-N-(4-метилбензил)-4-пиперидинамина; N-(4-фторбензил)-N-(4-фторфенил)-4-пиперидинамина; N-(4-фторфенил)-N-(4-метилбензил)-4-пиперидинамина или их фармацевтически приемлемых солей.
6. N-(4-Фторбензил)-N-(3-фторфенил)-4-пиперидинамин или его фармацевтически приемлемые соли.
7. N-(3-Фторфенил)-N-(4-метилбензил)-4-пиперидинамин или его фармацевтически приемлемые соли.
8. Фармацевтический препарат, содержащий в качестве активного ингредиента терапевтически эффективное количество соединения по п.п. от 1 до 7 и фармацевтически приемлемые вспомогательные вещества, разбавители или носители.
9. Соединение по любому из пп.1-7, предназначенное для использования в медицине.
10. Применение соединения по пп.1-7 для изготовления медикамента.
11. Применение соединения по пп.1-7 для изготовления медикамента для лечения неврологических заболеваний.
13. Способ по п.12, предназначенный для получения соединений, выбранных из группы, состоящей из трет-бутил-4-[3-фтор(4-фторбензил)анилино]-1-пиперидинкарбоксилата; трет-бутил-4-{[3-(трифторметил)бензил]-анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(3-хлорбензил)-анилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дифторбен-зил)анилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дихлор-бензил)анилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-метил-бензил)анилино]-1-пиперидинкарбоксилата; трет-бутил-4-{[4-(три-фторметил)бензил]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дифторбензил)-3-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-хлорбензил)-3-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дихлорбензил)-3-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[3-фтор(4-метилбензил)-анилино]-1-пиперидинкарбоксилата; трет-бутил-4-{3-фтор [4-(трифторметил)бензил]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(3-хлорбензил)-3-метиланилино]-1-пиперидинкарбоксилата;
трет-бутил-4-[(3,4-дифторбензил)-3-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-фторбензил)-3-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-хлорбензил)-3-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дихлор-бензил)-3-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-{3-метил[4-(трифторметил)бензил]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-(бензил-4-фторанилино)-1-пиперидинкарбоксилата; трет-бутил-4-{4-фтор[3-(трифторметил)бензил]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(3-хлорбензил)-4-фтор-анилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дифторбензил)-4-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[4-фтор(4-фторбензил)анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(4-хлорбензил)-4-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дихлорбензил)-4-фторанилино]-1-пиперидинкарбоксилата; трет-бутил-4-[4-фтор(4-метилбензил)анилино]-1-пиперидинкарбоксилата; трет-бутил-4-{4-фтор[4-(трифторметил)]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[4-хлор(4-фторбензил)-анилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3-хлорбензил)-4-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дифторбензил)-4-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-фторбензил)-4-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(4-хлорбензил)-4-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-[(3,4-дихлорбензил)-4-метиланилино]-1-пиперидинкарбоксилата; трет-бутил-4-{4-метил[4-(трифторметил)-бензил]анилино}-1-пиперидинкарбоксилата; трет-бутил-4-[(4-фторбензил)-4-(трифторметил)анилино]-1-пиперидинкарбоксилата и трет-бутил-4-[(3-хлорбензил)-3-фторанилино]-1-пиперидинкарбоксилата.
14. Способ по п.12, предназначенный для получения соединений, выбранных из группы, состоящей из трет-бутил-4-(3-фторанилино)-1-пиперидинкарбокси-лата; трет-бутил-4-(3-толуидино)-1-пиперидинкарбоксилата; трет-бутил 4-(4-толуидино)-1-пиперидинкарбоксилата.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02022191 | 2002-10-04 | ||
EP02022191.7 | 2002-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005110409A true RU2005110409A (ru) | 2005-09-10 |
Family
ID=32049973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005110409/04A RU2005110409A (ru) | 2002-10-04 | 2003-09-30 | Производные 4-аминопиперидина, способы их получения и использование в качестве медикаментов |
Country Status (21)
Country | Link |
---|---|
US (1) | US7488741B2 (ru) |
EP (2) | EP1556045B1 (ru) |
JP (1) | JP2006513151A (ru) |
KR (1) | KR20050055748A (ru) |
CN (1) | CN1688307A (ru) |
AT (1) | ATE334680T1 (ru) |
AU (1) | AU2003270291A1 (ru) |
BR (1) | BR0314811A (ru) |
CA (1) | CA2500664A1 (ru) |
DE (1) | DE60307308T2 (ru) |
DK (1) | DK1556045T3 (ru) |
ES (1) | ES2268406T3 (ru) |
MX (1) | MXPA05003290A (ru) |
NO (1) | NO20052172L (ru) |
NZ (1) | NZ539015A (ru) |
PL (1) | PL376368A1 (ru) |
PT (1) | PT1556045E (ru) |
RU (1) | RU2005110409A (ru) |
SI (1) | SI1556045T1 (ru) |
WO (1) | WO2004030668A1 (ru) |
ZA (1) | ZA200502330B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060079554A1 (en) * | 2002-12-06 | 2006-04-13 | Barry Peter C | Inhibitors of monomine uptake |
WO2005000811A1 (en) * | 2003-06-11 | 2005-01-06 | Eli Lilly And Company | 3-aminopyrrolidines as inhibitors of monoamine uptake |
WO2005053663A2 (en) * | 2003-11-24 | 2005-06-16 | Eli Lilly And Company | Norepinephrine reuptake inhibitors useful for treatment of cognitive failure |
US7615648B2 (en) * | 2004-06-01 | 2009-11-10 | Eli Lilly And Company | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake |
RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
BR112015022226A2 (pt) * | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
CA3102077A1 (en) | 2018-05-31 | 2019-12-05 | Sanjeev AHUJA | Method of reducing pulmonary exacerbations in respiratory disease patients |
CN111233751B (zh) * | 2020-03-25 | 2021-02-02 | 丽水绿氟科技有限公司 | 一种3,3-二氟-4-氨基哌啶类化合物及其衍生物的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG12406A (en) * | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
JPH05148234A (ja) * | 1991-10-02 | 1993-06-15 | Hokuriku Seiyaku Co Ltd | アルカン酸誘導体 |
DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
-
2003
- 2003-09-30 WO PCT/EP2003/010824 patent/WO2004030668A1/en active IP Right Grant
- 2003-09-30 ES ES03750658T patent/ES2268406T3/es not_active Expired - Lifetime
- 2003-09-30 EP EP03750658A patent/EP1556045B1/en not_active Expired - Lifetime
- 2003-09-30 DK DK03750658T patent/DK1556045T3/da active
- 2003-09-30 SI SI200330506T patent/SI1556045T1/sl unknown
- 2003-09-30 BR BR0314811-4A patent/BR0314811A/pt not_active IP Right Cessation
- 2003-09-30 AU AU2003270291A patent/AU2003270291A1/en not_active Abandoned
- 2003-09-30 NZ NZ539015A patent/NZ539015A/en unknown
- 2003-09-30 CN CNA03823730XA patent/CN1688307A/zh active Pending
- 2003-09-30 PT PT03750658T patent/PT1556045E/pt unknown
- 2003-09-30 US US10/528,924 patent/US7488741B2/en not_active Expired - Fee Related
- 2003-09-30 MX MXPA05003290A patent/MXPA05003290A/es not_active Application Discontinuation
- 2003-09-30 EP EP06008607A patent/EP1693061A1/en not_active Withdrawn
- 2003-09-30 AT AT03750658T patent/ATE334680T1/de not_active IP Right Cessation
- 2003-09-30 CA CA002500664A patent/CA2500664A1/en not_active Abandoned
- 2003-09-30 KR KR1020057005877A patent/KR20050055748A/ko not_active Application Discontinuation
- 2003-09-30 RU RU2005110409/04A patent/RU2005110409A/ru not_active Application Discontinuation
- 2003-09-30 PL PL03376368A patent/PL376368A1/xx not_active Application Discontinuation
- 2003-09-30 DE DE60307308T patent/DE60307308T2/de not_active Expired - Lifetime
- 2003-09-30 JP JP2004540745A patent/JP2006513151A/ja active Pending
-
2005
- 2005-03-18 ZA ZA200502330A patent/ZA200502330B/en unknown
- 2005-05-03 NO NO20052172A patent/NO20052172L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004030668A1 (en) | 2004-04-15 |
DE60307308D1 (de) | 2006-09-14 |
PT1556045E (pt) | 2006-12-29 |
ZA200502330B (en) | 2006-05-31 |
ATE334680T1 (de) | 2006-08-15 |
PL376368A1 (en) | 2005-12-27 |
SI1556045T1 (sl) | 2007-02-28 |
US7488741B2 (en) | 2009-02-10 |
NO20052172L (no) | 2005-06-30 |
JP2006513151A (ja) | 2006-04-20 |
EP1556045A1 (en) | 2005-07-27 |
DE60307308T2 (de) | 2006-12-28 |
DK1556045T3 (da) | 2006-11-27 |
AU2003270291A1 (en) | 2004-04-23 |
BR0314811A (pt) | 2005-08-02 |
CA2500664A1 (en) | 2004-04-15 |
US20060128753A1 (en) | 2006-06-15 |
KR20050055748A (ko) | 2005-06-13 |
NO20052172D0 (no) | 2005-05-03 |
EP1693061A1 (en) | 2006-08-23 |
CN1688307A (zh) | 2005-10-26 |
MXPA05003290A (es) | 2005-07-05 |
NZ539015A (en) | 2006-02-24 |
ES2268406T3 (es) | 2007-03-16 |
EP1556045B1 (en) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0604494B1 (en) | 5-ht4 receptor antagonists | |
AU629197B2 (en) | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes | |
US6534525B1 (en) | 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists | |
US20100168103A1 (en) | Diaryl piperidine compounds as calcium channel blockers | |
IL115040A (en) | Substituted piperidines useful for the treatment of allergic diseases process for their preparation and pharmaceutical compositions containing them | |
JP2000502690A (ja) | タキキニンレセプターアンタゴニストとしての1−(1,2−ジ置換ピペリジニル)−4−置換ピペリジン誘導体 | |
US20090253747A1 (en) | Remedy for sleep disturbance | |
JP2010518026A5 (ru) | ||
RU2009133336A (ru) | Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами | |
CA2466965A1 (en) | Sulphonamide derivatives, their preparation and use as medicaments | |
US6642226B2 (en) | Substituted phenyl-piperidine methanone compounds | |
RU2005110409A (ru) | Производные 4-аминопиперидина, способы их получения и использование в качестве медикаментов | |
KR19990028807A (ko) | 디페닐메틸렌 피페리딘 유도체 | |
KR102054208B1 (ko) | 신경성 기립 저혈압의 치료에 사용하기 위한 화합물 | |
EP1976841A1 (en) | Heterocyclic amide derivatives as calcium channel blockers | |
ZA200403688B (en) | Piperidine derivatives and their use as modulators of chemokine receptor activity (especialy CCR5). | |
JP2024514366A (ja) | 可溶性エポキシドヒドロラーゼ阻害剤としてのピペリジン尿素誘導体 | |
EP1289527B1 (en) | (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol or its prodrug to treat dementia or cognitive impairment | |
JP2008533082A5 (ru) | ||
IE65117B1 (en) | 1-(Pyridinylamino)-2-pyrrolidinones a process for their preparation and their use as medicaments | |
JPWO2008029924A1 (ja) | 環状アミノアルキルカルボキサミド誘導体 | |
JP2005535650A5 (ru) | ||
ZA200308344B (en) | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same. | |
CZ335495A3 (en) | N-substituted azaheterocyclic carboxylic acids and their esters, process of their preparation and pharmaceutical compositions containing thereof | |
US5086055A (en) | Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070921 |